389 related articles for article (PubMed ID: 19760604)
21. Loss of heterozygosity at chromosome 11p15 in Wilms tumors: identification of two independent regions.
Karnik P; Chen P; Paris M; Yeger H; Williams BR
Oncogene; 1998 Jul; 17(2):237-40. PubMed ID: 9674708
[TBL] [Abstract][Full Text] [Related]
22. Refinement within single yeast artificial chromosome clones of a minimal region commonly deleted on the short arm of chromosome 7 in Wilms tumours.
Perotti D; Testi MA; Mondini P; Pilotti S; Green ED; Pession A; Sozzi G; Pierotti MA; Fossati-Bellani F; Radice P
Genes Chromosomes Cancer; 2001 May; 31(1):42-7. PubMed ID: 11284034
[TBL] [Abstract][Full Text] [Related]
23. Duplication of the paternal IGF2 allele in trisomy 11 and elevated expression levels of IGF2 mRNA in congenital mesoblastic nephroma of the cellular or mixed type.
Watanabe N; Haruta M; Soejima H; Fukushi D; Yokomori K; Nakadate H; Okita H; Hata JI; Fukuzawa M; Kaneko Y
Genes Chromosomes Cancer; 2007 Oct; 46(10):929-35. PubMed ID: 17639583
[TBL] [Abstract][Full Text] [Related]
24. High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray.
Yin D; Ogawa S; Kawamata N; Tunici P; Finocchiaro G; Eoli M; Ruckert C; Huynh T; Liu G; Kato M; Sanada M; Jauch A; Dugas M; Black KL; Koeffler HP
Mol Cancer Res; 2009 May; 7(5):665-77. PubMed ID: 19435819
[TBL] [Abstract][Full Text] [Related]
25. Identification of a minimal region of loss on the short arm of chromosome 1 in Wilms tumor.
Tamimi Y; Ziebart K; Desaulniers N; Dietrich K; Grundy P
Genes Chromosomes Cancer; 2007 Apr; 46(4):327-35. PubMed ID: 17243164
[TBL] [Abstract][Full Text] [Related]
26. Clonality and loss of heterozygosity of WT genes are early events in the pathogenesis of nephroblastomas.
Guertl B; Ratschek M; Harms D; Jaenig U; Leuschner I; Poremba C; Hoefler G
Hum Pathol; 2003 Mar; 34(3):278-81. PubMed ID: 12673563
[TBL] [Abstract][Full Text] [Related]
27. Genome-wide loss of heterozygosity analysis of WT1-wild-type and WT1-mutant Wilms tumors.
Ruteshouser EC; Hendrickson BW; Colella S; Krahe R; Pinto L; Huff V
Genes Chromosomes Cancer; 2005 Jun; 43(2):172-80. PubMed ID: 15761866
[TBL] [Abstract][Full Text] [Related]
28. Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features.
Takahashi M; Yang XJ; Lavery TT; Furge KA; Williams BO; Tretiakova M; Montag A; Vogelzang NJ; Re GG; Garvin AJ; Söderhäll S; Kagawa S; Hazel-Martin D; Nordenskjold A; Teh BT
Cancer Res; 2002 Nov; 62(22):6598-605. PubMed ID: 12438255
[TBL] [Abstract][Full Text] [Related]
29. Cadherins in Wilms' tumor: E-cadherin expression despite absence of WT1.
Baudry D; Cabanis MO; Patte C; Zucker JM; Pein F; Fournet JC; Sarnacki S; Junien C; Jeanpierre C
Anticancer Res; 2003; 23(1A):475-8. PubMed ID: 12680252
[TBL] [Abstract][Full Text] [Related]
30. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
[TBL] [Abstract][Full Text] [Related]
31. Inherited and Sporadic Epimutations at the IGF2-H19 locus in Beckwith-Wiedemann syndrome and Wilms' tumor.
Riccio A; Sparago A; Verde G; De Crescenzo A; Citro V; Cubellis MV; Ferrero GB; Silengo MC; Russo S; Larizza L; Cerrato F
Endocr Dev; 2009; 14():1-9. PubMed ID: 19293570
[TBL] [Abstract][Full Text] [Related]
32. Mosaic allelic insulin-like growth factor 2 expression patterns reveal a link between Wilms' tumorigenesis and epigenetic heterogeneity.
Ohlsson R; Cui H; He L; Pfeifer S; Malmikumpu H; Jiang S; Feinberg AP; Hedborg F
Cancer Res; 1999 Aug; 59(16):3889-92. PubMed ID: 10463576
[TBL] [Abstract][Full Text] [Related]
33. Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis.
Gorringe KL; Ramakrishna M; Williams LH; Sridhar A; Boyle SE; Bearfoot JL; Li J; Anglesio MS; Campbell IG
Genes Chromosomes Cancer; 2009 Oct; 48(10):931-42. PubMed ID: 19603523
[TBL] [Abstract][Full Text] [Related]
34. Amplification and expression of EGFR and ERBB2 in Wilms tumor.
Vasei M; Modjtahedi H; Ale-Booyeh O; Mosallaei A; Kajbafzadeh AM; Shahriari M; Ghaderi AA; Soleymanpour H; Kosari F; Moch H; Sauter G
Cancer Genet Cytogenet; 2009 Oct; 194(2):88-95. PubMed ID: 19781441
[TBL] [Abstract][Full Text] [Related]
35. Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas.
Weber RG; Hoischen A; Ehrler M; Zipper P; Kaulich K; Blaschke B; Becker AJ; Weber-Mangal S; Jauch A; Radlwimmer B; Schramm J; Wiestler OD; Lichter P; Reifenberger G
Oncogene; 2007 Feb; 26(7):1088-97. PubMed ID: 16909113
[TBL] [Abstract][Full Text] [Related]
36. Analysis of a new homozygous deletion in the tumor suppressor region at 3p12.3 reveals two novel intronic noncoding RNA genes.
Angeloni D; ter Elst A; Wei MH; van der Veen AY; Braga EA; Klimov EA; Timmer T; Korobeinikova L; Lerman MI; Buys CH
Genes Chromosomes Cancer; 2006 Jul; 45(7):676-91. PubMed ID: 16607615
[TBL] [Abstract][Full Text] [Related]
37. Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays.
Wang L; Fidler C; Nadig N; Giagounidis A; Della Porta MG; Malcovati L; Killick S; Gattermann N; Aul C; Boultwood J; Wainscoat JS
Haematologica; 2008 Jul; 93(7):994-1000. PubMed ID: 18508791
[TBL] [Abstract][Full Text] [Related]
38. Fanconi anemia gene mutations are not involved in sporadic Wilms tumor.
Adank MA; Segers H; van Mil SE; van Helsdingen YM; Ameziane N; van den Ouweland AM; Wagner A; Meijers-Heijboer H; Kool M; de Kraker J; Waisfisz Q; van den Heuvel-Eibrink MM
Pediatr Blood Cancer; 2010 Oct; 55(4):742-4. PubMed ID: 20589654
[TBL] [Abstract][Full Text] [Related]
39. Combined BubR1 protein down-regulation and RASSF1A hypermethylation in Wilms tumors with diverse cytogenetic changes.
Haruta M; Matsumoto Y; Izumi H; Watanabe N; Fukuzawa M; Matsuura S; Kaneko Y
Mol Carcinog; 2008 Sep; 47(9):660-6. PubMed ID: 18286482
[TBL] [Abstract][Full Text] [Related]
40. Frequency and heritability of WT1 mutations in nonsyndromic Wilms' tumor patients: a UK Children's Cancer Study Group Study.
Little SE; Hanks SP; King-Underwood L; Jones C; Rapley EA; Rahman N; Pritchard-Jones K
J Clin Oncol; 2004 Oct; 22(20):4140-6. PubMed ID: 15483024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
